{"id":"cilostazol-tablets","safety":{"commonSideEffects":[{"rate":"27","effect":"Headache"},{"rate":"19","effect":"Diarrhea"},{"rate":"5","effect":"Palpitations"},{"rate":"9","effect":"Dizziness"},{"rate":"4","effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL799","moleculeType":"Small molecule","molecularWeight":"369.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking PDE-3 in vascular smooth muscle and platelets, cilostazol elevates cyclic adenosine monophosphate (cAMP), which leads to vasodilation of blood vessels and reduced platelet clumping. This dual action improves blood flow and reduces thrombotic events, making it effective for peripheral arterial disease and stroke prevention.","oneSentence":"Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:23.467Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Intermittent claudication due to peripheral arterial disease"},{"name":"Secondary prevention of ischemic stroke"}]},"trialDetails":[{"nctId":"NCT03855332","phase":"PHASE2","title":"Oxford Haemodynamic Adaptation to Reduce Pulsatility Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-07-11","conditions":"Small Vessel Cerebrovascular Disease","enrollment":75},{"nctId":"NCT06919835","phase":"PHASE3","title":"CiLostAzol for pReventIon of Recurrent sTroke in Africa","status":"NOT_YET_RECRUITING","sponsor":"Northern California Institute of Research and Education","startDate":"2025-12-01","conditions":"Stroke","enrollment":1100},{"nctId":"NCT07174414","phase":"PHASE3","title":"Cilostazol for Prevention of Recurrent Stroke Trial","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-08","conditions":"Stroke Recurrence, Myocardial Infarction, Vascular Death","enrollment":2000},{"nctId":"NCT07144956","phase":"PHASE3","title":"Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier St Anne","startDate":"2025-12-15","conditions":"Aneurysmal Subarachnoid Hemorrhage","enrollment":630},{"nctId":"NCT06591338","phase":"PHASE3","title":"Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-01","conditions":"Ischemic Stroke","enrollment":900},{"nctId":"NCT04789837","phase":"PHASE1, PHASE2","title":"The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-03-01","conditions":"Osteoarthritis","enrollment":""},{"nctId":"NCT04761848","phase":"PHASE1, PHASE2","title":"Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2021-02-16","conditions":"Fatty Liver, Nonalcoholic","enrollment":""},{"nctId":"NCT04410341","phase":"PHASE1, PHASE2","title":"The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients","status":"WITHDRAWN","sponsor":"Sadat City University","startDate":"2020-05-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT07040085","phase":"PHASE3","title":"Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-08-05","conditions":"Stroke","enrollment":892},{"nctId":"NCT06989697","phase":"PHASE3","title":"Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes","status":"RECRUITING","sponsor":"Seoul National University Bundang Hospital","startDate":"2025-01-01","conditions":"Type 2 Diabets Mellitus, Cognitive Ability, General","enrollment":80},{"nctId":"NCT06886620","phase":"PHASE3","title":"Assess the Safety and Effectiveness of Once Daily PMR Compared to Twice Daily Pletaal® in Patients With Intermittent Claudication","status":"TERMINATED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2016-03-14","conditions":"Intermittent Claudication","enrollment":14},{"nctId":"NCT05191862","phase":"PHASE1","title":"Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers","status":"TERMINATED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2022-04-23","conditions":"Intermittent Claudication","enrollment":19},{"nctId":"NCT06117436","phase":"PHASE2, PHASE3","title":"Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-19","conditions":"Wound Heal","enrollment":206},{"nctId":"NCT03451591","phase":"PHASE2, PHASE3","title":"LACunar Intervention (LACI-2) Trial-2","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2018-01-08","conditions":"Cerebral Small Vessel Diseases, Stroke, Lacunar","enrollment":363},{"nctId":"NCT06612593","phase":"PHASE2","title":"Cilostazol in Parkinson's Disease","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-10-01","conditions":"Parkinson's Disease","enrollment":50},{"nctId":"NCT06242132","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2022-06-01","conditions":"Ischemic Stroke","enrollment":870},{"nctId":"NCT06242145","phase":"PHASE3","title":"Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2023-01-01","conditions":"Ischemic Stroke","enrollment":580},{"nctId":"NCT00839930","phase":"PHASE1","title":"Cilostazol 50 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-02","conditions":"Healthy","enrollment":30},{"nctId":"NCT00838630","phase":"PHASE1","title":"Cilostazol 100 mg Tablet Formulations Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2003-11","conditions":"Healthy","enrollment":36},{"nctId":"NCT00648388","phase":"PHASE1","title":"Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-03","conditions":"Healthy","enrollment":44},{"nctId":"NCT06167265","phase":"PHASE1","title":"BE Study of Once Daily PMR Compared to Twice Daily Cilostazol Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2023-11-28","conditions":"Intermittent Claudication","enrollment":40},{"nctId":"NCT06138834","phase":"PHASE2","title":"EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-11","conditions":"Acute Ischemic Stroke, Large Vessel Occlusion, Reperfusion","enrollment":300},{"nctId":"NCT05836766","phase":"PHASE2","title":"Cilostazol Dexborneol Versus Placebo for Microcirculation Dysfunction After Reperfusion Therapy in Patients With Acute Ischemic Stroke With Large Vessel Occlusion","status":"UNKNOWN","sponsor":"Beijing Tiantan Hospital","startDate":"2023-06-05","conditions":"Acute Ischemic Stroke, Reperfusion, Large Vessel Occlusion","enrollment":120},{"nctId":"NCT05466734","phase":"PHASE1","title":"BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2022-07-05","conditions":"Intermittent Claudication","enrollment":25},{"nctId":"NCT04069819","phase":"NA","title":"The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.","status":"COMPLETED","sponsor":"Sadat City University","startDate":"2019-08-01","conditions":"Major Depressive Disorder","enrollment":80},{"nctId":"NCT01142284","phase":"PHASE2","title":"Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-05-19","conditions":"Peripheral Artery Disease","enrollment":80},{"nctId":"NCT03581409","phase":"PHASE4","title":"Comparison of Two Different Antiplatelet Preparations for an Unruptured Intracranial Aneurysm","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2018-10-24","conditions":"Aneurysm, Cerebral, Endovascular Procedures","enrollment":198},{"nctId":"NCT00766545","phase":"PHASE3","title":"Cilostazol Stroke Prevention Study : A Placebo-controlled Double-blind Trial for Secondary Prevention of Cerebral Infarction.","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"1992-04","conditions":"Cerebral Infarction","enrollment":1095},{"nctId":"NCT04407312","phase":"PHASE4","title":"Cilostazol and Endothelial Progenitor Cell","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","startDate":"2016-01-01","conditions":"Myocardial Infarction, Acute","enrollment":60},{"nctId":"NCT03422796","phase":"NA","title":"The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2017-11-01","conditions":"Migraine","enrollment":30},{"nctId":"NCT00822172","phase":"PHASE4","title":"Evaluation of Cilostazol in Combination With L-Carnitine","status":"COMPLETED","sponsor":"Colorado Prevention Center","startDate":"2008-09","conditions":"Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease","enrollment":164},{"nctId":"NCT01291641","phase":"PHASE4","title":"Effect of Probucol and/or Cilostazol on Mean IMT in Patients With Coronary Heart dIsease","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2011-03","conditions":"Hyperlipidemias","enrollment":342},{"nctId":"NCT03864666","phase":"PHASE1","title":"Bioequivalence Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2019-02-11","conditions":"Intermittent Claudication","enrollment":28},{"nctId":"NCT01995370","phase":"PHASE4","title":"Cilostazol Stroke Prevention Study for Antiplatelet Combination","status":"COMPLETED","sponsor":"Japan Cardiovascular Research Foundation","startDate":"2013-12-13","conditions":"Noncardioembolic Cerebral Infarction","enrollment":1884},{"nctId":"NCT03480321","phase":"PHASE1","title":"Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Genovate Biotechnology Co., Ltd.,","startDate":"2018-03-06","conditions":"Intermittent Claudication","enrollment":21},{"nctId":"NCT00602173","phase":"NA","title":"Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2003-05","conditions":"Intermittent Claudication","enrollment":32},{"nctId":"NCT00602407","phase":"NA","title":"Bioequivalency Study of 50 mg Cilostazol Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-02","conditions":"Intermittent Claudication","enrollment":36},{"nctId":"NCT03156920","phase":"NA","title":"Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2017-05-23","conditions":"Migraine","enrollment":30},{"nctId":"NCT02486276","phase":"NA","title":"The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache","status":"COMPLETED","sponsor":"Danish Headache Center","startDate":"2015-06","conditions":"Migraine","enrollment":30},{"nctId":"NCT02087007","phase":"PHASE3","title":"A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2013-11","conditions":"Vasospastic Angina","enrollment":100},{"nctId":"NCT00881231","phase":"PHASE1","title":"To Demonstrate the Relative Bioavailability of Cilostazol 50 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-01","conditions":"Pain","enrollment":26},{"nctId":"NCT02933788","phase":"PHASE4","title":"Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients","status":"UNKNOWN","sponsor":"Kangbuk Samsung Hospital","startDate":"2016-10","conditions":"Type 2 Diabetes Mellitus","enrollment":116},{"nctId":"NCT01895400","phase":"PHASE3","title":"Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy","status":"TERMINATED","sponsor":"Jong Woo Chung","startDate":"2013-07","conditions":"Recurrent Vestibulopathy","enrollment":26},{"nctId":"NCT02194686","phase":"PHASE4","title":"Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2013-01","conditions":"Cardiovascular Diseases","enrollment":71},{"nctId":"NCT02174939","phase":"PHASE4","title":"Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2014-02","conditions":"Coronary Artery Disease","enrollment":300},{"nctId":"NCT01952756","phase":"PHASE4","title":"Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2012-01","conditions":"Peripheral Arterial Diseases","enrollment":44},{"nctId":"NCT01378650","phase":"NA","title":"A Study on the Effect of Cilostazol in Patients With Chronic Tinnitus","status":"COMPLETED","sponsor":"Jong Woo Chung","startDate":"2011-07","conditions":"Tinnitus","enrollment":50},{"nctId":"NCT01188824","phase":"PHASE4","title":"The Safety and Efficacy of Cilostazol in Ischemic Stroke Patients With Peripheral Arterial Disease (SPAD Study)","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2010-09","conditions":"Ischemic Stroke","enrollment":801},{"nctId":"NCT01444885","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-10","conditions":"Variant Angina","enrollment":50},{"nctId":"NCT00783081","phase":"PHASE2","title":"Safety and Efficacy of K-134 for the Treatment of Intermittent Claudication","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2008-11","conditions":"Intermittent Claudication","enrollment":387},{"nctId":"NCT01455558","phase":"PHASE1","title":"Safety and Pharmacokinetic Comparison of Cilostazol SR and IR Formulations in Healthy Korean Volunteers","status":"COMPLETED","sponsor":"Severance Hospital","startDate":"2009-02","conditions":"Healthy","enrollment":92},{"nctId":"NCT00773630","phase":"PHASE1","title":"A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions","status":"COMPLETED","sponsor":"Otsuka Frankfurt Research Institute GmbH","startDate":"2008-12","conditions":"Intermittent Claudication","enrollment":44},{"nctId":"NCT00234065","phase":"PHASE4","title":"Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2003-12","conditions":"Cerebral Infarction","enrollment":2800},{"nctId":"NCT00823875","phase":"PHASE4","title":"Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-03","conditions":"Atherosclerosis Cerebral Infarction","enrollment":200},{"nctId":"NCT01076478","phase":"PHASE4","title":"Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical, Inc., Philippines","startDate":"2004-03","conditions":"Polyneuropathy","enrollment":47},{"nctId":"NCT00446641","phase":"PHASE4","title":"Overcome Biochemical Aspirin Resistance Through Cilostazol Combination","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2007-03","conditions":"Cerebral Infarction","enrollment":244},{"nctId":"NCT00685802","phase":"PHASE1","title":"Fasted Bioavailability Study of Cilostazol Tablets, 50mg","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2004-06","conditions":"Therapeutic Equivalency, Healthy","enrollment":32},{"nctId":"NCT00684762","phase":"PHASE1","title":"Fasted Bioavailability Study of Cilostazol Tablets, 100 mg","status":"COMPLETED","sponsor":"Mutual Pharmaceutical Company, Inc.","startDate":"2004-03","conditions":"Therapeutic Equivalency","enrollment":32},{"nctId":"NCT00272831","phase":"PHASE4","title":"The Use of Cilostazol in Patients With Diabetic Nephropathy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2, Diabetes Complications","enrollment":62},{"nctId":"NCT00573950","phase":"PHASE4","title":"Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness","status":"UNKNOWN","sponsor":"Korea University Anam Hospital","startDate":"2007-12","conditions":"Diabetes Mellitus, Type 2, Metabolic Syndrome X","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cilostazol-SR"],"phase":"marketed","status":"active","brandName":"Cilostazol Tablets","genericName":"Cilostazol Tablets","companyName":"Gyeongsang National University Hospital","companyId":"gyeongsang-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cilostazol inhibits phosphodiesterase-3 (PDE-3) to increase cAMP levels, promoting vasodilation and inhibiting platelet aggregation. Used for Intermittent claudication due to peripheral arterial disease, Secondary prevention of ischemic stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}